Further analyses in the context of other molecular aberrations have shown that patients with NPM1-mutated AML who have a normal karyotype and lack FLT3-ITD (representing about 30% of all AML cases) have a better prognosis. Here, FLT3 is linked to acute myeloid leukemia.